LAV694

lavendustin derivative; an antiproliferative agent showing improved skin tolerability vs. clinical standards for the treatment of actinic keratosism

Networked: 1 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Elsaesser, Christian: 1 article (11/2003)
2.	Fraissinette, Anne de Brugerolle de: 1 article (11/2003)
3.	Greiner, Brigitte: 1 article (11/2003)
4.	Kolopp, Maryelle: 1 article (11/2003)
5.	Mahl, Andreas: 1 article (11/2003)
6.	Medina, Jesús: 1 article (11/2003)
7.	Meingassner, Josef: 1 article (11/2003)
8.	Nussbaumer, Peter: 1 article (11/2003)
9.	Picarles, Valérie: 1 article (11/2003)
10.	Roman, Danielle: 1 article (11/2003)

Related Diseases

1.	Actinic Keratosis 11/15/2003 - "LAV694, a new antiproliferative agent showing improved skin tolerability vs. clinical standards for the treatment of actinic keratosis."
2.	Necrosis 11/15/2003 - "In conclusion, LAV694 selectively induced apoptosis, rather than necrosis, of growth-arrested keratinocytes, thus avoiding the occurrence of extensive inflammation. "
3.	Inflammation (Inflammations) 11/15/2003 - "In conclusion, LAV694 selectively induced apoptosis, rather than necrosis, of growth-arrested keratinocytes, thus avoiding the occurrence of extensive inflammation. "